The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers

NCT02838589 · Completed

Last updated 2026-05-28

This trial tests whether a GLP-1 receptor agonist affects blood flow and oxygen levels in the brain of healthy volunteers who have not had a stroke.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 30 people

Who can join Ages 50+ · all sexes Healthy volunteers accepted.

Timeline Started 2016-08 · est. completion 2017-02

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT02838589 ↗

Description as written by the study sponsor.

This randomized controlled trial investigates the effect of a single dose of glucagon-like peptide-1 (GLP-1) receptor agonist on cerebral blood flow velocity and cortical oxygination in humans without cerebrovascular disease. This study serves as a control for a similar study investigating the effect in stroke patients (ref. to EGRABIS1).

Treatments tested

Byetta also known as exenatide, GLP-1 receptor analogue, GLP-1 receptor agonist Drug

Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
Isotonic saline also known as Normal saline Drug

Single dose of subcutaneous injection of 20 μL isotonic saline (placebo).

Main thing measured	Changes in the mean flow velocity in the middle cerebral arteries and in cortical oxigination .
Sponsor	Christina Kruuse
Conditions studied	Stroke
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02838589 ↗